Robotics in Cell Therapy Manufacturing Market Size, Trends and Forecast 2026 to 2035

What is Robotics in Cell Therapy Manufacturing Market Size?

Global Robotics in Cell Therapy Manufacturing Market Size is valued at USD 1.68 Bn in 2025 and is predicted to reach USD 6.38 Bn by the year 2035 at a 14.5% CAGR during the forecast period for 2026 to 2035.

Robotics in Cell Therapy Manufacturing Market Size, Share & Trends Analysis Report By Component (Hardware, Software, Services); By Cell Type (T-cells, Stem cells, Natural Killer Cells, Other cell types); By Manufacturing Process Stage (Upstream Processing, Downstream Processing, Fill-Finish Operations, Quality Control (QC)); By Robotics Type (Industrial Robotics, Collaborative Robots, Fully Automated Closed Systems, AI-driven/Smart Robotics); By End-User (Pharmaceutical Companies, Biotechnology Companies, Contract Manufacturing Organizations (CMOs), Research Institutes, Academic Hospitals), and Segment Forecasts, 2026 to 2035

Robotics in cell therapy manufacturing involves the integration of advanced robotic systems, automation technologies, and intelligent process controls to streamline the production of cell-based therapies. These systems automate critical and labor-intensive steps, including cell isolation, expansion, harvesting, formulation, quality control testing, filling, and cryopreservation.

By replacing manual operations with high-precision robotic platforms, manufacturers can achieve superior batch-to-batch consistency, significantly reduce the risk of contamination, minimize human error, and ensure compliance with stringent Good Manufacturing Practice (GMP) and regulatory requirements. As cell and gene therapies advance from clinical trials toward commercial-scale production, robotics has become a critical enabler for improving manufacturing efficiency, scalability, product quality, and cost-effectiveness in this rapidly evolving sector.

The global robotics in cell therapy manufacturing market is showing rapid expansion owing to the rising amount of investment in regenerative medicine, increase in clinical trials, and approval of cell-based therapies all over the world. There is an investment in developing advanced manufacturing capabilities, thereby providing opportunities for automation technology. Additionally, the use of artificial intelligence, machine vision, and digital manufacturing systems is enabling companies to streamline their processes, thereby improving their efficiency and productivity.
Moreover, there is a trend towards closed-system manufacturing and smart bioprocessing facilities within the sector. Such trends are expected to improve reliability as well as accommodate the large-scale manufacturing needs of the next generation of cell therapies. With the demand for personalized medicine on the rise, robotics will play a pivotal role in future manufacturing.

Competitive Landscape

Which are the Leading Players in Robotics in Cell Therapy Manufacturing Market?

• Thermo Fisher Scientific Inc.
• Cytiva
• Lonza Group AG
• Sartorius AG
• Miltenyi Biotec
• Fresenius Kabi AG
• Danaher Corporation
• Cellares Corporation
• Multiply Labs
• Ori Biotech
• Cellino Biotech
• Terumo Corporation
• ABB Ltd.
• FANUC Corporation
• Yaskawa Electric Corporation
• Kawasaki Robotics
• Bio-Techne Corporation
• Catalent Inc.
• Fujifilm Holdings Corporation
• BioNTech SE

Market Dynamics :

Driver

Growing Commercialization of Cell and Gene Therapies

Increased commercialization of cell and gene therapies is likely to be one of the key factors driving the global robotics in cell therapy manufacturing market during the forecast period. The growing commercialization of advanced therapies is encouraging manufacturers to adopt more efficient and streamlined production methods. Furthermore, growing investment in regenerative medicine and personalized healthcare will fuel the deployment of automation technologies in manufacturing plants. With the help of robotics technology, manufacturers can ensure higher production rates along with quality standards. Regulatory approvals for various cell-based therapies will also contribute towards increased demand.

Restrain/Challenge

High Capital Investment and Manufacturing Complexity

Among the primary obstacles that are hindering the growth of the robotics in cell therapy manufacturing market is the high cost involved in incorporating automation technologies. There are several factors that make automation expensive and can therefore discourage smaller biotech firms from adopting robotics for cell therapy manufacturing. Besides the technical complexity of cell therapy manufacturing process that makes it unique and specialized, the incorporation of robotics technology into cell therapy manufacturing becomes difficult. Moreover, there could also be shortage of qualified workers due to limited number of experts who are experienced in robotic techniques and biomanufacturing technologies. 

Biopharmaceutical Companies Segment is Expected to Drive the Robotics in Cell Therapy Manufacturing Market

The segment of biopharmaceutical companies had the maximum share in the market for robotics in the manufacturing of cell therapies in the year 2025. Growth in the number of commercial-stage cell therapies and increased investments in the infrastructure for manufacturing have compelled biopharmaceutical companies to embrace modern automation solutions. Robotics technology plays an important role in achieving process standardization, lowering costs, and meeting large-scale manufacturing requirements. In addition, manufacturers are using robotic systems to speed up development and increase manufacturing agility. With the growing pipeline of cell therapies, biopharmaceutical companies will continue to dominate the market over the forecast period.

Artificial Intelligence-Enabled Robotics Segment is Growing at the Highest Rate in the Robotics in Cell Therapy Manufacturing Market

In 2025, artificial intelligence-driven robotics will be the primary driver of market growth since it allows better process control, predictive maintenance, and decision making. AI-driven robotic systems can make analysis of vast quantities of data related to manufacturing processes in real-time for workflow optimization. With the growing popularity of machine learning, computer vision, and analytics applied to robots, the efficiency of the manufacturing process and final products will continue to increase. Organizations that strive for greater automation of their production facilities will increasingly use AI-based robotics solutions.

Why North America Led the Robotics in Cell Therapy Manufacturing Market?

North America held the majority share of the Robotics in Cell Therapy Manufacturing market in 2025, due to the high level of investment in biotechnology research, superior manufacturing capabilities, and supportive regulations. The presence of key players involved in cell therapies, contract manufacturing companies, and automation technologies has been contributing to the fast adoption of robots for manufacturing purposes.

Moreover, funding for regenerative medicine studies along with their commercialization efforts has led to an increased need for robotics technology. The US remains a prominent location for the development and manufacturing of cell therapies.

Key Developments

•    In June 2025: Thermo Fisher Scientific partnered with Cellular Origins to combine Thermo Fisher’s cell culture and processing technologies with the Constellation robotic manufacturing platform. The collaboration aims to enable fully automated, 24/7 robotic manufacturing of cell and gene therapies (CGTs) at industrial scale, reducing labor requirements and increasing manufacturing throughput.

Robotics in Cell Therapy Manufacturing Market Report Scope:

Report Attribute	Specifications
Market size value in 2025	USD 1.68 Bn
Revenue forecast in 2035	USD 6.38 Bn
Growth Rate CAGR	CAGR of 14.5% from 2026 to 2035
Quantitative Units	Representation of revenue in US$ Bn and CAGR from 2026 to 2035
Historic Year	2022 to 2025
Forecast Year	2026-2035
Report Coverage	The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends
Segments Covered	Component, Cell Type, Manufacturing Process Stage, Robotics Type, End-user, and By Region
Regional Scope	North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country Scope	U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia
Competitive Landscape	Thermo Fisher Scientific Inc., Cytiva, Lonza Group AG, Sartorius AG, Miltenyi Biotec, Fresenius Kabi AG, Danaher Corporation, Cellares Corporation, Multiply Labs, Ori Biotech, Cellino Biotech, Terumo Corporation, ABB Ltd., FANUC Corporation, Yaskawa Electric Corporation, Kawasaki Robotics, Bio-Techne Corporation, Catalent Inc., Fujifilm Holdings Corporation, and BioNTech SE.
Customization Scope	Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape.
Pricing and Available Payment Methods	Explore pricing alternatives that are customized to your particular study requirements.